& Lassen, A
GnanapavanSKolaBBustinSAMorrisDGMcGeePFaircloughPet al
Key variants assessed include GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313, each affecting weight-loss trajectory and medication tolerance
L-Glutathione) l mt tripeptit ni sinh c tng hp t 3 axit amin (cysteine, glutamic v glycine) ti gan
Monitor aluminum levels in at risk patients (5.1) Allergic Reactions: to thiamine may occur (5.2) Hypervitaminosis A: Patients with renal failure or liver disease may be at higher risk (5.3) Decreased Anticoagulant Effect of Warfarin: Periodically monitor prothrombin time (5.4) Interferes with Megaloblastic Anemia Diagnosis: Avoid use during testing for this disorder (5.5) Risk of Vitamin Deficiencies or Excesses: Monitor blood vitamin concentrations (5.6) False Negative Urine Glucose Tests: May occur due to vitamin C (5.7) Risk of Vitamin E Toxicity: Additional oral and parenteral vitamin E may result in elevated vitamin E blood concentrations in infants (5.8) Low Vitamin A Levels: Monitor vitamin A levels (5.9) Risk of E- Ferol Syndrome: due to polysorbates (5.10) Adverse Reactions/Side Effects Adverse reactions have included anaphylaxis, rash, erythema, pruritus, headache, dizziness, agitation, anxiety, diplopia, urticaria, shortness of breath, wheezing and angioedema (6) To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc
